Filters

Choose one market

Market access pathways by country

Explore how an innovative medicine moves from approval to patient access.

Selected market

Austria

Outpatient reimbursement uses the EKO red, yellow and green box process with social insurance decision making. Hospital medicines sit outside EKO and depend on state/hospital financing, formulary and procurement.

EC/EMA or BASG

applicant / Dachverband

HEK

Dachverband

federal Price Commission / ministry

8 decision nodes11 cited sources

For education only — not regulatory, pricing or legal advice.

About the content and how to use it

Evidence checked through 2026-08-06A pathway is a decision map—not a launch-time promise

Locate the relevant route first

These choices define how to read the branches below. They do not predict a payer or provider decision.

1

Which Austrian sector applies?EKO applies to outpatient reimbursement, not hospital funding.

Selected routeOutpatient EKO8 applicable nodes

Authorization-to-patient timeline

See the selected route reach the patient

Updates immediately when a choice changes

1

Austria-valid marketing authorisationroute selection and lawful supply

2

Sector and EKO applicationHEK evaluationSelected branch

3

HEK evaluation and recommendationDachverband decision

4

Dachverband EKO decisionprescriber/insurer/pharmacy executionSelected branch

5

Price Commission reviewEKO price compliance/refund

6

Selected hospital Bewertungsboardhospital medicines committee

7

Hospital list, budget and procurementfirst eligible patient

8

First funded patientEligible patient + capable provider + authorization + product + clean payment

1Confirm outpatient or inpatient sector

2Read the current EKO box and prescribing conditions

3Align price with the competent payer

4Verify hospital budget, formulary and stock

Do not collapse these decisions

EKO box status, EU average pricing, hospital budget, formulary approval and acquisition price must not be treated as one decision.

Decision map

What each local node actually produces

Select a row to inspect legal effect and downstream gates

#Local decision / ownerDecision outputDownstream dependencyEvidence

Decision question

Is quality, safety and efficacy acceptable for the claimed use?

Required evidence / materials

CTD, clinical/nonclinical evidence, RMP, German product information

Can iterate or branch

centralised, MRP/DCP, national, variation

Source date

AT-S01 · current procedure；AT-S11 · 2026-08-19

Node linked to cited dossier sourcesProduct/provider execution still requires live verification

Special mechanisms and lifecycle

What can reopen price, coverage or procurement after launch

Dates below come from the cited policy record—not a product forecast

Mechanism / triggerDecision outputIteration / branchPolicy recordLatest observed

First funded patient and lifecycle controldispensed/administered treatment and paid claimprice review, reassessment, competitor, shortage or delistingAT-S03 · AT-S06current at check

EKO box reassignmentPrice reviewHospital tender renewalGeneric/biosimilar entry

Evidence & policy library

Official basis and policy dates

11 records · checked 2026-08-06